CN Patent

CN102369011A — 用于治疗造血恶性肿瘤的磷酸肌醇3-激酶抑制剂化合物与化学治疗剂的组合

Assigned to Genentech Inc · Expires 2012-03-07 · 14y expired

What this patent protects

本发明涉及具有式I的PI3K抑制剂化合物包括其立体异构体、几何异构体、互变异构体、代谢物和可药用盐与化学治疗剂的组合，用于治疗造血恶性肿瘤。本发明披露使用所述组合体外、原位和体内诊断、预防或治疗哺乳动物细胞所述障碍或相关病理性病症的方法。

USPTO Abstract

本发明涉及具有式I的PI3K抑制剂化合物包括其立体异构体、几何异构体、互变异构体、代谢物和可药用盐与化学治疗剂的组合，用于治疗造血恶性肿瘤。本发明披露使用所述组合体外、原位和体内诊断、预防或治疗哺乳动物细胞所述障碍或相关病理性病症的方法。

Drugs covered by this patent

cobimetinib-fumarate (COBIMETINIB FUMARATE)

Patent Metadata

Patent number: CN102369011A
Jurisdiction: CN
Classification: —
Expires: 2012-03-07
Drug substance claim: No
Drug product claim: No
Assignee: Genentech Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.